AI-generated analysis. Always verify with the original filing.
Karyopharm Therapeutics Inc. entered a Securities Purchase Agreement with RA Capital Management to issue shares, pre-funded warrants, and common stock warrants in a private placement expected to yield $30 million gross proceeds, with potential additional $44 million upon warrant exercise. The company announced topline results from the Phase 3 SENTRY trial meeting the SVR35 co-primary endpoint with 50% of patients achieving spleen volume reduction versus 28% on ruxolitinib alone.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securit
Unregistered Sales of Equity Securities. The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. The s
(including Exhibits 99.1, 99.2 and 99.3) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 193
Other Events. SENTRY Trial Topline Data On March 24, 2026, the Company announced topline results from its SENTRY trial in which patients were randomized 2:1 to
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant to Purchase Common Stock 4.2 Form of Warrant to Purchase
Material Agreement